Add-on levetiracetam in children and adolescents with refractory epilepsy: Results of an open-label multi-centre study

European Journal of Paediatric Neurology

Volumn 12, Issue 4, 2008, Pages 321-327

  Callenbach, Petra M C ^a   Arts, Willem Frans M ^b   ten Houten, Robert ^c   Augustijn, Paul ^d   Gunning, W Boudewijn ^e   Peeters, Els A J ^f   Weber, Alma M ^e   Stroink, Hans ^g   Geerts, Yvette ^d   Geerts, Ada T ^b   Brouwer, Oebele F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Location Alkmaar   (Netherlands)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^e EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^f JULIANA CHILDREN S HOSPITAL   (Netherlands)

^g CPRLab   (Netherlands)

Author keywords

Add on; Children; Efficacy; Levetiracetam; Refractory epilepsy; Tolerability

Indexed keywords

ETIRACETAM;

ACADEMIC ACHIEVEMENT; ADD ON THERAPY; ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; APPETITE; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GINGIVA DISEASE; HAIR LOSS; HUMAN; HYPERACTIVITY; HYPERSALIVATION; IRRITABILITY; LETHARGY; MALE; MAXIMUM PERMISSIBLE DOSE; MENTAL CONCENTRATION; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; REMISSION; SIDE EFFECT; SOMNOLENCE; WEIGHT;

ADOLESCENT; ANTICONVULSANTS; CHILD; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE MOOD; MALE; PIRACETAM; PROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME;

EID: 43749107871     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2007.09.004     Document Type: Article

References (18)

1. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85 (2000) 77-85
2. Pellock J.M., Glauser T.A., Bebin E.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
3. Fountain N.B., Conry J.A., Rodriguez-Leyva I., et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res 74 (2007) 60-69
4. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
5. Glauser T.A., Pellock J.M., Bebin E.M., et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
6. Wheless J.W., and Ng Y.T. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 17 (2002) 413-415
7. Nakken K.O., Eriksson A.S., Lossius R., and Johannessen S.I. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 12 (2003) 42-46
8. Lagae L., Buyse G., Deconinck A., and Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 7 (2003) 123-128
9. Tan M.J., and Appleton R.E. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 13 (2004) 142-145
10. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 14 (2005) 66-71
11. Grosso S., Franzoni E., Coppola G., et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 14 (2005) 248-253
12. Opp J., Tuxhorn I., May T., et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 14 (2005) 476-484
13. Glauser T.A., Ayala R., Elterman R.D., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
14. Peake D., Mordekar S., Gosalakkal J., et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure 16 (2007) 185-189
15. Grosso S., Cordelli D.M., Franzoni E., et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure 16 (2007) 345-350
16. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22 (1981) 489-501
17. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
18. Coupez R., Straetemans R., Sehgal G., Stockis A., and Lu Z.S. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J Clin Pharmacol 43 (2003) 1370-1376